Alyson Haslam
Publishes 1 feed
The Oncology Shot with Timothee Olivier
My Personal Substack
10 posts · contributor
Lately
Beyond Cross-Trial Comparisons: What Digitized Survival Curves Can Really Tell Us
Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?
EMA and FDA Advocate Removing Amgen’s Drug from the Market: How Unblinded Personnel Manipulated the ADVOCATE Trial
Additional Insights Into Early Daraxonrasib Data
World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial
RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution?
An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.
The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies.
An outstanding source of trial data lacking from publications: IQWiG assessment reports. The NIAGARA trial example.
My IQWiG lecture in Cologne! What a great audience and team!
Everything on this page was read from markup Alyson Haslam published — a rel="me" link, an h-card, or the feed’s own author element. Nothing was inferred from anywhere else. To correct or remove it, get in touch. Machine-readable: JSON